Radiotherapy for Growing Vestibular Schwannomas.

IF 5.6 1区 医学 Q1 OTORHINOLARYNGOLOGY
Mantegh Sethi, Shravan Gowrishankar, James Tysome, Neil Donnelly, Patrick Axon, Manohar Bance, Richard Mannion, Mathew Guilfoyle, Juliette Buttimore, Nicola Gamazo, Simon Duke, Raj Jena, Katherine Burton, Sarah Jefferies, Umberto Fornezza, Zeno Perini, Cristina Mari, Luca Gazzola, Sammy Schouten, Inge Compter, Daniëlle B P Eekers, Henricus P M Kunst, Rohan Bassi, Samuel MacKeith, Sanjeeva Jeyaretna, Gillian Whitfield, Catherine McBain, Rovel Colaco, Angus Hotchkies, Simon Lloyd, Rupert Obholzer, Ya Fang Amanda Cheang, Nick Thomas, Sinan Barazi, Eleni Maratos, Jonathan Shapey, Sheila Hassan, Kazumi Chia, Cornel Tancu, Neil Kitchen, John P Marinelli, Matthew L Carlson, Michael J Link, Daniele Borsetto
{"title":"Radiotherapy for Growing Vestibular Schwannomas.","authors":"Mantegh Sethi, Shravan Gowrishankar, James Tysome, Neil Donnelly, Patrick Axon, Manohar Bance, Richard Mannion, Mathew Guilfoyle, Juliette Buttimore, Nicola Gamazo, Simon Duke, Raj Jena, Katherine Burton, Sarah Jefferies, Umberto Fornezza, Zeno Perini, Cristina Mari, Luca Gazzola, Sammy Schouten, Inge Compter, Daniëlle B P Eekers, Henricus P M Kunst, Rohan Bassi, Samuel MacKeith, Sanjeeva Jeyaretna, Gillian Whitfield, Catherine McBain, Rovel Colaco, Angus Hotchkies, Simon Lloyd, Rupert Obholzer, Ya Fang Amanda Cheang, Nick Thomas, Sinan Barazi, Eleni Maratos, Jonathan Shapey, Sheila Hassan, Kazumi Chia, Cornel Tancu, Neil Kitchen, John P Marinelli, Matthew L Carlson, Michael J Link, Daniele Borsetto","doi":"10.1001/jamaoto.2025.1953","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>In the literature, there is a lack of data reporting tumor control rates after radiotherapy in actively growing vestibular schwannomas (VS). Data for this rarely studied population are needed.</p><p><strong>Objective: </strong>To estimate tumor control rates in radiologically growing VS treated with first-line radiotherapy.</p><p><strong>Design, setting, and participants: </strong>This international, multicenter cohort study used prospectively collected data from patients with growing unilateral VS treated first-line with radiotherapy between January 2000 and December 2023 from 8 tertiary referral skull base units. The data were analyzed in June 2025.</p><p><strong>Exposures: </strong>Radiotherapy as an initial treatment for VS.</p><p><strong>Main outcomes and measures: </strong>The primary outcome was treatment failure, ie VS growth postradiotherapy, which was predefined as an increase in maximum intracranial tumor diameter (ICTD) of 3 mm or greater within the first 2 years after radiotherapy or 2 mm or greater thereafter. Secondary outcomes were treatment failure based on different definitions of VS growth: (1) an increase in ICTD of 2 mm or greater, (2) an increase in ICTD of 3 mm or greater, and (3) conversion to surgery.</p><p><strong>Results: </strong>A total of 1883 patients (975 female individuals [51.8%]; median age at diagnosis, 63 years [IQR, 53-71 years]) were included in the study. Using the primary definition of treatment failure (an increase in ICTD of ≥3 mm within the first 2 years postradiotherapy or ≥2 mm thereafter), the Kaplan-Meier estimate yielded a 10-year tumor control rate of 76.1% (95% CI, 72.7%-79.2%). For secondary outcome definitions, 10-year tumor control rates were 60.1% (95% CI, 57.5%-64.3%) for an ICTD increase of 2 mm or greater, 78.3% (95% CI, 75.0%-81.2%) for an increase of 3 mm or greater, and 92.6% (95% CI, 90.4%-94.3%) for conversion to surgery. Neither pretreatment tumor size nor tumor location (intracanalicular vs extracanalicular) were significantly associated with treatment failure.</p><p><strong>Conclusions and relevance: </strong>The results of this cohort study provide tumor control outcomes for radiologically growing VS treated with radiotherapy using several clinically relevant definitions of growth. By focusing exclusively on this rarely isolated subgroup, the findings offer targeted data to potentially inform treatment expectations and future research.</p>","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412036/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA otolaryngology-- head & neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamaoto.2025.1953","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: In the literature, there is a lack of data reporting tumor control rates after radiotherapy in actively growing vestibular schwannomas (VS). Data for this rarely studied population are needed.

Objective: To estimate tumor control rates in radiologically growing VS treated with first-line radiotherapy.

Design, setting, and participants: This international, multicenter cohort study used prospectively collected data from patients with growing unilateral VS treated first-line with radiotherapy between January 2000 and December 2023 from 8 tertiary referral skull base units. The data were analyzed in June 2025.

Exposures: Radiotherapy as an initial treatment for VS.

Main outcomes and measures: The primary outcome was treatment failure, ie VS growth postradiotherapy, which was predefined as an increase in maximum intracranial tumor diameter (ICTD) of 3 mm or greater within the first 2 years after radiotherapy or 2 mm or greater thereafter. Secondary outcomes were treatment failure based on different definitions of VS growth: (1) an increase in ICTD of 2 mm or greater, (2) an increase in ICTD of 3 mm or greater, and (3) conversion to surgery.

Results: A total of 1883 patients (975 female individuals [51.8%]; median age at diagnosis, 63 years [IQR, 53-71 years]) were included in the study. Using the primary definition of treatment failure (an increase in ICTD of ≥3 mm within the first 2 years postradiotherapy or ≥2 mm thereafter), the Kaplan-Meier estimate yielded a 10-year tumor control rate of 76.1% (95% CI, 72.7%-79.2%). For secondary outcome definitions, 10-year tumor control rates were 60.1% (95% CI, 57.5%-64.3%) for an ICTD increase of 2 mm or greater, 78.3% (95% CI, 75.0%-81.2%) for an increase of 3 mm or greater, and 92.6% (95% CI, 90.4%-94.3%) for conversion to surgery. Neither pretreatment tumor size nor tumor location (intracanalicular vs extracanalicular) were significantly associated with treatment failure.

Conclusions and relevance: The results of this cohort study provide tumor control outcomes for radiologically growing VS treated with radiotherapy using several clinically relevant definitions of growth. By focusing exclusively on this rarely isolated subgroup, the findings offer targeted data to potentially inform treatment expectations and future research.

生长的前庭神经鞘瘤的放射治疗。
重要性:在文献中,缺乏报道主动生长的前庭神经鞘瘤(VS)放疗后肿瘤控制率的数据。需要这一很少被研究的人群的数据。目的:评价放射学生长性VS一线放疗的肿瘤控制率。设计、环境和参与者:这项国际、多中心队列研究前瞻性地收集了2000年1月至2023年12月8个三级转诊颅底单位的单侧VS患者的一线放疗数据。这些数据是在2025年6月进行分析的。主要结局和措施:主要结局是治疗失败,即放疗后VS生长,其预先定义为放疗后前2年内最大颅内肿瘤直径(ICTD)增加3mm或更大,之后增加2mm或更大。次要结局是基于VS生长的不同定义的治疗失败:(1)ICTD增加2mm或更大,(2)ICTD增加3mm或更大,(3)转为手术。结果:共纳入1883例患者,其中女性975例(51.8%),诊断时中位年龄63岁[IQR, 53-71岁]。使用治疗失败的主要定义(放疗后2年内ICTD增加≥3mm或放疗后≥2mm), Kaplan-Meier估计10年肿瘤控制率为76.1% (95% CI, 72.7%-79.2%)。对于次要结局定义,ICTD增加2毫米或更大的10年肿瘤控制率为60.1% (95% CI, 57.5%-64.3%),增加3毫米或更大的10年肿瘤控制率为78.3% (95% CI, 75.0%-81.2%),转行手术的10年肿瘤控制率为92.6% (95% CI, 90.4%-94.3%)。预处理肿瘤大小和肿瘤位置(管内vs管外)与治疗失败均无显著相关性。结论和相关性:该队列研究的结果为放疗治疗放射学上生长的VS提供了肿瘤控制结果,使用了几种临床相关的生长定义。通过专门关注这个很少孤立的亚组,研究结果提供了有针对性的数据,可能为治疗预期和未来的研究提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.10
自引率
5.10%
发文量
230
期刊介绍: JAMA Otolaryngology–Head & Neck Surgery is a globally recognized and peer-reviewed medical journal dedicated to providing up-to-date information on diseases affecting the head and neck. It originated in 1925 as Archives of Otolaryngology and currently serves as the official publication for the American Head and Neck Society. As part of the prestigious JAMA Network, a collection of reputable general medical and specialty publications, it ensures the highest standards of research and expertise. Physicians and scientists worldwide rely on JAMA Otolaryngology–Head & Neck Surgery for invaluable insights in this specialized field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信